Canadian real-world study of aripiprazole LAI in schizophrenia



Presented at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, Miami, Florida, May 29 – June 1, 2018

The first Canadian naturalistic study in patients with schizophrenia has reported high rates of remission rates and low rates of relapse with long-acting aripiprazole over a one-year period (Oluboka et al. ASCP 2018; abstract).

The ReLiAM study (Real Life Assessment of Abilify Maintena) evaluated 169 patients with schizophrenia. The primary endpoint was the change from baseline in functioning as evaluated by the Global Assessment of Functioning (GAF) scale. The mean change was 12.2 points at 12 months, with greater improvement (mean change 14.1 points) observed in early-phase patients (≤5 years from diagnosis). There were also significant improvements in symptom severity, as assessed by the Brief Psychiatric Rating Scale (BPRS), CGI-Severity and CGI-Improvement scales. Treatment with aripiprazole once-monthly also resulted in significant improvements in all seven items of the Quality of Life (QLS)-7 scale.

Click the play button below for a full discussion of the results by investigator Dr. Toba Oluboka, University of Calgary.

Recommend to a Colleague

Related Posts

Go back to home page